June 5th 2025
Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
New Drugs, Vaccines Continue to Advance in the Global Fight Against MERS-CoV: Public Health Watch
May 23rd 2018The virus associated with the Middle East may or may not pose a threat to the United States, but researchers here are still working hard to find treatments and preventative vaccines.
Read More
Preventing Emerging Infectious Disease Epidemics: Nipah R&D Roadmap
May 17th 2018In the wake of the Ebola epidemic in West Africa, the World Health Organization is working with the Center for Infectious Disease Research and Policy and the Wellcome Trust to create research & development roadmaps for priority diseases, such as Nipah virus.
Read More